ArticleMolecular cancer research : MCR2012
Group I p21-activated kinases (PAKs) promote tumor cell proliferation and survival through the AKT1 and Raf-MAPK pathways.
Article in Molecular cancer research : MCR, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 56 citations in OpenAlex.
- Inactivation of p21-Activated Kinase 2 (Pak2) Inhibits the Development of Nf2-Deficient Tumors by Restricting Downstream Hedgehog and Wnt Signaling.Molecular cancer research : MCR · 2022Article
- Impact of neoadjuvant chemotherapy on somatic mutation status in high-grade serous ovarian carcinoma.Journal of ovarian research · 2022Article
- DNA repair and damage pathways in mesothelioma development and therapy.Cancer cell international · 2022Review
- Synthetic dysmobility screen unveils an integrated STK40-YAP-MAPK system driving cell migration.Science advances · 2021Article
- Ras, TrkB, and ShcA Protein Expression Patterns in Pediatric Brain Tumors.Journal of clinical medicine · 2021Article
- Multifaceted p21 in carcinogenesis, stemness of tumor and tumor therapy.World journal of stem cells · 2020Review
- The dynactin subunit DCTN1 controls osteoclastogenesis via the Cdc42/PAK2 pathway.Experimental & molecular medicine · 2020Article
- P21 activated kinase 2 promotes pancreatic cancer growth and metastasis.Oncology letters · 2019Article
- Development of an integrated CRISPRi targeting ΔNp63 for treatment of squamous cell carcinoma.Oncotarget · 2018Article
- IGF1R signaling drives antiestrogen resistance through PAK2/PIX activation in luminal breast cancer.Oncogene · 2018Article
- Targeted silencing of SOX2 by an artificial transcription factor showed antitumor effect in lung and esophageal squamous cell carcinoma.Oncotarget · 2017Article
- Knowledge-guided gene prioritization reveals new insights into the mechanisms of chemoresistance.Genome biology · 2017Article
- Deciphering the link between PI3K and PAK: An opportunity to target key pathways in pancreatic cancer?Oncotarget · 2017Review
- Targeting MYC sensitizes malignant mesothelioma cells to PAK blockage-induced cytotoxicity.American journal of cancer research · 2017Article
- Optimization of Highly Kinase Selective Bis-anilino Pyrimidine PAK1 Inhibitors.ACS medicinal chemistry letters · 2016Article
- Article
- SOX2 suppresses CDKN1A to sustain growth of lung squamous cell carcinoma.Scientific reports · 2016Article
- PAK2 promotes migration and proliferation of salivary gland adenoid cystic carcinoma.American journal of translational research · 2016Article
- Pak2 restrains endomitosis during megakaryopoiesis and alters cytoskeleton organization.Blood · 2015Article
- microRNA-126 suppresses PAK4 expression in ovarian cancer SKOV3 cells.Oncology letters · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Group I p21-activated kinases (PAK) are important effectors of the small GTPases Rac and Cdc42, which regulate cell motility/migration, survival, proliferation, and gene transcription. Hyperactivation of these kinases have been reported in many tumor types, making PAKs attractive targets for therapeutic intervention. PAKs are activated by growth factor-mediated signaling and are negatively regulated by the tumor suppressor neurofibromatosis type 2 (NF2)/Merlin. Thus, tumors characterized by NF2 inactivation would be expected to show hyperactivated PAK signaling. On the basis of this rationale, we evaluated the status of PAK signaling in malignant mesothelioma, an aggressive neoplasm that is resistant to current therapies and shows frequent inactivation of NF2. We show that group I PAKs are activated in most mesotheliomas and mesothelioma cell lines and that genetic or pharmacologic inhibition of PAKs is sufficient to inhibit mesothelioma cell proliferation and survival. We also identify downstream effectors and signaling pathways that may contribute mechanistically to PAK-related tumorigenesis. Specifically, we show that inhibition of PAK results in attenuation of AKT and Raf-MAPK signaling and decreased tumor cell viability. Collectively, these data suggest that pharmacologic inhibition of group I PAKs may have therapeutic efficacy in tumors characterized by PAK activation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.